Mr. ScoreCarder wrote "companies can have phase 3 data doubling the SOC mOS in difficult to treat cancers and not have deals even then."
If true, it would be interesting to understand why. Small intended patient population, death and side effects risk, etc. etc.? Some things that leronlimab has not shown proclivities toward.
But first, why don't you substantiate your claim with some links or publications showing the names of these companies, their situations and the validity of your supposition?
If true, it would be interesting to understand why. Small intended patient population, death and side effects risk, etc. etc.? Some things that leronlimab has not shown proclivities toward.
But first, why don't you substantiate your claim with some links or publications showing the names of these companies, their situations and the validity of your supposition?
15